StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the stock.
Oragenics Stock Down 5.6 %
Shares of Oragenics stock opened at $1.53 on Wednesday. Oragenics has a 52-week low of $1.00 and a 52-week high of $7.74. The business has a 50 day moving average price of $1.61. The stock has a market capitalization of $6.85 million, a P/E ratio of -0.18 and a beta of 0.58.
Oragenics (NYSE:OGEN – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share (EPS) for the quarter.
Institutional Trading of Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Five stocks we like better than Oragenics
- How Investors Can Find the Best Cheap Dividend Stocks
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Following Congress Stock Trades
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- Comparing and Trading High PE Ratio Stocks
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.